MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Jazz Pharmaceuticals plc DSO Ratio 2011-2026 | JAZZ
Annual DSO Ratio Jazz Pharmaceuticals plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.2 | 63.8 | 64.6 | 60.6 | 56.6 | 58.1 | 60.1 | 50.9 | 50.5 | 57.4 | 57.8 | 58 | 52.2 | 47 | 46.1 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 66.2 | 46.1 | 56.7 |
Quarterly DSO Ratio Jazz Pharmaceuticals plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.9 | 59.6 | 70 | 61.5 | 62.6 | 67.5 | 58.1 | 58.8 | 65.2 | - | 29.2 | 28 | 63.7 | - | 54.8 | 55.9 | 60.9 | 54.4 | 60.2 | 64.3 | 64.2 | 55.8 | 60.4 | 60.8 | 55.6 | 50.5 | 51.3 | 48.1 | 50.1 | 46.9 | 49.7 | 51.9 | 55.6 | 53.9 | 57.1 | 56.1 | 60.3 | 56.1 | 56.1 | 57.3 | 58.4 | 51.8 | 55.5 | 58.4 | 57.5 | 48.3 | 49 | 54.7 | 46.6 | 37.5 | 39.2 | 55.4 | 48.9 | 37.5 | 42.8 | 48.6 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70 | 28 | 54.1 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Cerus Corporation
CERS
|
47 | $ 2.72 | 33.99 % | $ 518 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 21.95 | -2.23 % | $ 3.64 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
182 | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.71 | -1.16 % | $ 114 M | USA |
 |
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
60.8 | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Editas Medicine
EDIT
|
142 | $ 2.9 | -3.33 % | $ 257 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
56.5 | - | - | $ 2.02 B | USA |
 |
Edesa Biotech
EDSA
|
97.1 | $ 17.59 | -3.75 % | $ 56.2 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 2.93 | -8.15 % | $ 4.82 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
39.7 | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
157 | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.81 | 3.33 % | $ 27.9 M | Israel |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |